Compounds > antrocin

Page last updated: 2024-11-13

antrocin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

antrocin: from Antrodia camphorata; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	53474706
SCHEMBL ID	12238041
MeSH ID	M0557910

Synonyms (2)

Synonym
antrocin
SCHEMBL12238041

Research Excerpts

Treatment

Antrocin treatment suppressed the viability, migration colony formation and mammosphere generation.

Excerpt	Reference	Relevance
"Antrocin treatment suppressed breast tumorigenesis and stemness properties."	( Antrocin, a bioactive component from Antrodia cinnamomea, suppresses breast carcinogenesis and stemness via downregulation of β-catenin/Notch1/Akt signaling. Chao, TY; Chen, JH; Huang, CC; T H Wu, A; T W Tzeng, D; Tzeng, YM, 2019)	2.68
"Antrocin treatment suppressed the viability, migration colony formation and mammosphere generation. "	( Antrocin, a bioactive component from Antrodia cinnamomea, suppresses breast carcinogenesis and stemness via downregulation of β-catenin/Notch1/Akt signaling. Chao, TY; Chen, JH; Huang, CC; T H Wu, A; T W Tzeng, D; Tzeng, YM, 2019)	3.4

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (57.14)	24.3611
2020's	3 (42.86)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	38.46 (24.57)
Research Supply Index	2.08 (2.92)
Research Growth Index	4.64 (4.65)
Search Engine Demand Index	34.82 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (38.46)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	7 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
cyanides Cyanides: Inorganic salts of HYDROGEN CYANIDE containing the -CN radical. The concept also includes isocyanides. It is distinguished from NITRILES, which denotes organic compounds containing the -CN radical.. cyanides : Salts and C-organyl derivatives of hydrogen cyanide, HC#N.. isocyanide : The isomer HN(+)#C(-) of hydrocyanic acid, HC#N, and its hydrocarbyl derivatives RNC (RN(+)#C(-)).. cyanide : A pseudohalide anion that is the conjugate base of hydrogen cyanide.	2.25	1	0	pseudohalide anion	EC 1.9.3.1 (cytochrome c oxidase) inhibitor
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.21	1	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
trimethylsilyl cyanide [no description available]	2.25	1	0
paxilline paxilline: structure given in first source; RN given refers to (2R-(2alpha,4bbeta,6aalpha,12bbeta,12calpha,14abeta))-isomer. paxilline : An indole diterpene alkaloid with formula C27H33NO4 isolated from Penicillium paxilli. It is a potent inhibitor of large conductance Ca2(+)- and voltage-activated K(+) (BK)-type channels.	2.13	1	0	diterpene alkaloid; enone; organic heterohexacyclic compound; terpenoid indole alkaloid; tertiary alcohol	anticonvulsant; Aspergillus metabolite; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor; genotoxin; geroprotector; mycotoxin; Penicillium metabolite; potassium channel blocker
sorafenib [no description available]	2.6	1	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
tartaric acid tartaric acid: RN given refers to cpd with unspecified isomeric designation. D-tartaric acid : The D-enantiomer of tartaric acid.	2.25	1	0	tartaric acid	Escherichia coli metabolite
farnesyl pyrophosphate farnesyl pyrophosphate: a sesquiterpene that dimerizes to SQUALENE; RN given refers to cpd without isomeric designation. 2-trans,6-trans-farnesyl diphosphate : The trans,trans-stereoisomer of farnesyl diphosphate.	2.6	1	0	farnesyl diphosphate	Escherichia coli metabolite; mouse metabolite
pyrophosphate Diphosphates: Inorganic salts of phosphoric acid that contain two phosphate groups.	2.6	1	0	diphosphate ion
sesquiterpenes [no description available]	3.56	7	0
ovatodiolide ovatodiolide: from Anisomeles indica; structure in first source	7.6	1	0
drimane drimane: structure in first source	2.6	1	0	sesquiterpene; terpenoid fundamental parent

Condition	Indicated	Relationship Strength	Studies	Trials
Hepatocellular Carcinoma [description not available]	0	7.6	1	0
Cancer of Liver [description not available]	0	2.6	1	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	0	2.6	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	0	2.6	1	0
Breast Cancer [description not available]	0	7.83	3	0
Metastase [description not available]	0	2.25	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	0	2.83	3	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	2.25	1	0
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	0	7.21	1	0
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	0	2.21	1	0
Carcinoma, Non-Small Cell Lung [description not available]	0	2.08	1	0
Cancer of Lung [description not available]	0	2.08	1	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	0	2.08	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	2.08	1	0
Bladder Cancer [description not available]	0	7.13	1	0
Invasiveness, Neoplasm [description not available]	0	2.13	1	0
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	0	2.13	1	0
Benign Neoplasms [description not available]	0	2.06	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	2.06	1	0